J&J's abiraterone improves survival in first Phase III prostate cancer trial
This article was originally published in Scrip
Johnson & Johnson's billion dollar acquisition of Cougar Biotechnology last year to gain access to a novel, hormonal anticancer, looks like it may be paying off; abiraterone acetate - which works in a different way to standard hormonal therapies in prostate cancer - improved overall survival in its first Phase III trial in men with advanced/metastatic prostate cancer who had progressed on previous hormonal therapy and chemotherapy.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.